Prostatic Cancer Clinical Trial
Official title:
An Open-Label, Phase II Safety, Tolerability, Drug Level and Efficacy Trial of Quinacrine in Patients With Androgen-Independent Metastatic Prostate Cancer
The purpose of this study is to determine whether quinacrine is effective in the treatment of Androgen-Independent Prostate Cancer.
Despite a modest improvement in survival with available chemotherapy treatments,
androgen-independent metastatic prostate cancer remains essentially incurable.
Several changes in gene function that characterize malignancy have been identified. For
example the p53 gene in normal tissue lessens the risk of cancer through growth arrest or
cell suicidal programs. Thus the silenced p53 gene present in cancer tissue contributes to
the growth of the cancer. In addition when the p53 gene is silenced, a cell survival
pathway, controlled by the NF-kB gene, is activated leading increased cell survival.
Quinacrine can activate p53 and inhibit NF-kB, thus reestablishing cell suicidal programs
and decreasing cell survival in cancer tissue. Moreover, quinacrine is effective against
several prostate tumor cell lines in vitro, and has anti-tumor effects against prostate
cancer xenografts in mice.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT05191017 -
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
|
Phase 1/Phase 2 | |
| Completed |
NCT00970203 -
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01086956 -
Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy
|
N/A | |
| Completed |
NCT00643617 -
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
|
N/A | |
| Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02687308 -
Open Anterograde Radical Prostatectomy Compared to Open Retrograde Technique
|
N/A | |
| Completed |
NCT01284608 -
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
|
N/A | |
| Completed |
NCT04421781 -
Salvage HIFU for Local Recurrence in the Prostatic Bed After Prostatectomy and External Beam Radiation Therapy : Preliminary Results
|
||
| Recruiting |
NCT05740956 -
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Enrolling by invitation |
NCT03173924 -
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05851521 -
To Evaluate LUTS and Complications Between Indwelling Catheter and Temporary Prostatic Stent in Patients Undergoing Minimally Invasive Procedures for the Treatment of Localized Prostate Cancer or Benign Prostatic Hyperplasia (HERMES)
|
N/A | |
| Completed |
NCT01998685 -
Prothrombotic Factors and Anaesthesia in Prostate Cancer
|
N/A | |
| Completed |
NCT01477749 -
Sipuleucel-T Manufacturing Demonstration Study
|
Phase 2 | |
| Not yet recruiting |
NCT06439784 -
Contribution of the VERITON-CT Camera in Prostate Bone Radiostereotaxy
|
N/A | |
| Terminated |
NCT03606889 -
Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia
|
N/A | |
| Completed |
NCT03481816 -
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
|
Phase 1 | |
| Completed |
NCT01171729 -
Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05623878 -
68Ga-labeled NY108 PET Imaging in Patients
|
Early Phase 1 | |
| Not yet recruiting |
NCT05184790 -
LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
|
||
| Completed |
NCT02564120 -
North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)
|